Eniagor
A branded Apsen combination at phase 3 in men with androgenetic alopecia.
- Developed by
- Apsen Farmacêutica
- Current phase
- Phase 3
- Indications
- Androgenetic alopecia
- Also known as
- APSMNF, APSMNF 1, APSMNF 2
- Last public activity
- April 2026
- Record confidence
- Low
Large confirmatory trials. The last step before filing.
Why it matters
The third Brazilian registrational programme in this register, and the only one with a brand name attached, which usually means a launch is planned rather than a licence sought. Two dose arms are registered under one study; the composition is not disclosed.
Development history
- Phase 3
First Phase 3 trial on record: NCT07516561 — Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia
Apsen Farmaceutica S.A. · n=336 · July 2026
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Eniagor in men with androgenetic alopecia — ClinicalTrials.gov